In the News
Boost for Alzheon’s targeted Alzheimer’s candidate
thepharmaletter.com
Neurodegenerative Treatments Build to a Tipping Point
Genetic Engineering & Biotechnology News (GEN)
Take A Pill For It! Approach to Alzheimer’s Disease
Bloomer Boomer
Generation Bold Interview with Alzheon CEO Martin Tolar
Alzheon CEO, Martin Tolar MD, PhD, interviews with Adriane Berg of Generation Bold on Alzheimer’s, ALZ-801 and the learnings from previous drug failures. Click below to listen [...]
Press Releases
Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801 Oral Tablet at Clinical Trials in Alzheimer’s Disease (CTAD) Conference
Baseline Data in Early Alzheimer’s Disease Shows Significant Differences in CSF Biomarker Profiles Between APOE4/4 Homozygotes and APOE3/4 Heterozygotes Validating Patient Selection for APOLLOE4 Phase 3 Study with ALZ-801 Tablet
Alzheon to Present at H.C. Wainwright Annual Global Investment Conference on September 13, 2021
Alzheon CEO Dr. Martin Tolar Will Provide Overview of Company Business and Update on Oral Anti-Amyloid ALZ-801 Phase 3 Program in Alzheimer’s Disease
Alzheon Appoints Adem Albayrak as Head of Operations and Earvin Liang, PhD, as Vice President of Clinical Development
New Hires Bring Extensive Precision Medicine and Clinical Development Expertise as Alzheon Advances Phase 2 & 3 Trials of ALZ-801 Tablet in Alzheimer’s Disease
Alzheon Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801 Oral Tablet in APOE4 Carriers with Alzheimer’s Disease
Study Evaluates Biomarker Evidence of Disease Modification in APOE4 Carriers, Who Comprise Two-Thirds of All Alzheimer’s Patients
Peer-Reviewed Scientific Publication Demonstrates Central Role of Neurotoxic Soluble Amyloid Oligomers in Driving Alzheimer’s Pathogenesis
Inhibition of Amyloid Toxicity Represents the Only Clinically Validated Approach for Slowing Progression of Alzheimer’s Disease
Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ 801 in Patients with Early Alzheimer’s Disease
Study to Confirm ALZ-801 Effects on Cognition and Function in High-Risk Patients with APOE4/4 Genotype